ArticleMedicine2013
Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection: A 15-Year Prospective Study.
Article in Medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Activation-induced cytidine deaminase in B cells of hepatits C virus-related cryoglobulinaemic vasculitis.Clinical and experimental immunology · 2015Trial
- Mixed cryoglobulinemia decelerates hepatocellular carcinoma development in hepatitis C patients with SVR by downregulating regulatory B cells: a 12-year prospective cohort study.Oncoimmunology · 2025Article
- Post-Treatment Occurrence of Serum Cryoglobulinemia in Chronic Hepatitis C Patients.Diagnostics (Basel, Switzerland) · 2024Article
- Cryoglobulinemia: the "cold" problem in cardiac surgery, a single-center experience and a literature review.Journal of anesthesia, analgesia and critical care · 2024Review
- The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements.Clinical and experimental medicine · 2023Review
- Secular trends in cryoglobulinemia mortality in the USA in the era of direct-acting antivirals.Arthritis research & therapy · 2022Article
- PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases.Liver international : official journal of the International Association for the Study of the Liver · 2021Article
- Understanding the Cryoglobulinemias.Current rheumatology reports · 2019Review
- Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.World journal of gastroenterology · 2019Article
- Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis.Clinical and experimental medicine · 2019Review
- Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience.Arthritis research & therapy · 2017Article
- The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review.Clinical and experimental medicine · 2016Review
- Hepatitis C virus - associated B cell non-Hodgkin's lymphoma.World journal of gastroenterology · 2016Review
- Delineation of autoantibody repertoire through differential proteogenomics in hepatitis C virus-induced cryoglobulinemia.Scientific reports · 2016Article
- Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.World journal of gastroenterology · 2015Review
- Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins.Medicine · 2015Observational
- HCV Treatments and Their Integration Into Rheumatology.Current rheumatology reports · 2015Review
- Thymic stromal lymphopoietin in hepatitis C virus-related cryoglobulinemic vasculitis: gene expression level and protein distribution.Arthritis research & therapy · 2015Article
- Management of patients with hepatitis C infection and renal disease.World journal of hepatology · 2015Review
- Neurologic manifestations of acute and chronic liver disease.Continuum (Minneapolis, Minn.) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the influence of cryoglobulinemic syndrome (CS) on the outcome of chronic hepatitis C virus (HCV) infection in a 15-year prospective study. We assessed a cohort of 950 chronically HCV-infected patients, collected from the beginning of 1990 to the end of 2010. All patients had received a liver histologic diagnosis. Mixed cryoglobulinemia (MC) was determined in 246 patients (25.8%), of whom 184 also had CS. They were assessed every 3 months for 15 years, at least; 141 patients with CS and 601 without MC completed the study.No spontaneous clearance of cryoglobulins was noted. Type II to type III spontaneous switching was ascertained in 1.6% (0.08%/yr) patients. The estimated progression rate of liver fibrosis was lower in CS(+) than in MC(-) patients (p < 0.05). The 15-year cumulative probability of developing cirrhosis and/or hepatocellular carcinoma was higher in MC(-) than in CS(+) patients (24.9% vs. 14.2%, p < 0.005 and 20.3% vs. 7.5%, p = 0.003, respectively). Renal insufficiency, neurologic impairment, or B-cell non-Hodgkin lymphoma were significantly more frequent in CS(+) than in MC(-) patients (32.6% vs. 3%, p < 0.0001; 31.2% vs. 4.8%, p < 0.0001; and 15% vs. 7.1%, p = 0.003, respectively). However, in spite of different morbidity features and causes of death, the 15-year survival rate was similar in the 2 groups (70.2% vs. 71.7%). Antiviral therapy had an undisputable impact on patient outcome.This 15-year prospective cohort study shows that, although CS has no influence on the overall survival of HCV-infected patients, it significantly modifies the natural history of chronically HCV-infected patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.